See every side of every news story
Published loading...Updated

XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease

Summary by Intelligence360 News
– Financing round led by new investor Jeito Capital with participation from existing investors – Proceeds will support two double-blind Phase 2 clinical trials of lead candidate, XC001, which has demonstrated transformative potential for treatment of refractory angina January 07, 2025 07:30 AM Eastern Standard Time KING OF PRUSSIA, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics, Inc., (“XyloCor”), a clinical stage biopharmaceutical company developing …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Intelligence360 News broke the news in on Thursday, January 16, 2025.
Sources are mostly out of (0)